



لیلا فرمند

دانشیار

محل خدمت: پژوهشکده سرطان معتمد

سوابق تحصیلی

مقطع تحصیلی	سال اخذ مدرک	رشته و گرایش تحصیلی	دانشگاه
دکترای تخصصی	۱۳۸۷	زیست فناوری دارویی	دانشگاه علوم پزشکی تهران

اطلاعات استخدامی

محل خدمت	عنوان سمت	نوع استخدام	نوع همکاری	پایه
دفتر مرکزی	مدیر کل دفتر تخصصی علوم پزشکی	رسمی قطعی	تمام وقت	

سوابق اجرایی

عضو هیات علمی پژوهشکده سرطان معتمد جهاددانشگاهی

مقالات در همایش ها

- محمد سعید خالدی ذیمه، لیلا فرمند، عباس شیری، گرمان مقدور مکران، واکاوی اثرات اردوهای دانش آموزی بر تربیت اجتماعی و فرهنگی آنان، دومین همایش بین المللی جامعه شناسی، علوم اجتماعی و آموزش و پرورش با رویکرد نگاهی به آینده، ۱۴۰۳.
- عباس شیری، لیلا فرمند، گرمان مقدور مکران، محمد سعید خالدی ذیمه، بررسی رابطه عزت نفس با پیشرفت تحصیلی در دانش آموزان، دومین همایش بین المللی جامعه شناسی، علوم اجتماعی و آموزش و پرورش با رویکرد نگاهی به آینده، ۱۴۰۳.
- سیده عصمت عبدالله زاده، لیلا فرمند، منوچهر دلاوری، محسن محسن نژاد، بررسی نقش آموزشی و تربیتی معلمان در بهبود سلامت روانی دانش آموزان، چهاردهمین کنفرانس ملی حقوق، علوم اجتماعی و انسانی، روانشناسی و مشاوره، ۱۴۰۲.
- علی دیدار، سمیه رسولی عباس آباد، لیلا فرمند، سیدعاصم حسن زاده، اخلاق کار اسلامی معلمان از منظر آیات و روایات، هشتمین کنفرانس بین المللی علوم تربیتی، روانشناسی، مشاوره، آموزش و پژوهش، ۱۴۰۲.
- لیلا فرمند، امیر طاهری، ندا جلیلی، ملیحه صالحی، مریم آهنی، تولید گانزوگه تراستوزومب با داروی شیمی درمانی مایتانسینوئید در مقیاس آزمایشگاهی، پنجمین کنفرانس ملی نوآوری و فناوری علوم زیستی، شیمی ایران، ۱۴۰۰.

مقالات در نشریات

- Yadegari, F., Farahmand, L., Esmaeili, R., Zarinfam, S., Majidzadeh, A., K., Inter-BRCT linker is probably the most intolerant region of the BRCA1 BRCT domain, Journal of Biomolecular Structure and Dynamics, 2024.
- Khodaverdi, E., Shabani, A.A., Madanchi, H., Farahmand, L., Synthesis of the scFv fragment of

anti-Frizzled-7 antibody and evaluation of its effects on triple-negative breast cancer in vitro .study,Clinical and Translational Oncology,2024

Shokrollahi Barough, M., Jalili, N., Shafiee, S., (...), Hosseinzadeh, A., Farahmand, L.,Anti-MUC1 .3
nanobody can synergize the Tamoxifen and Herceptin effects on breast cancer cells by inducing
.ER, PR and HER2 overexpression,International Immunopharmacology,2023

Mirzaei, R., Shafiee, S., Vafaei, R., (...), Reza Esmailinejad, M., Farahmand, L.,Production of .4
novel recombinant anti-EpCAM antibody as targeted therapy for breast cancer,International
.Immunopharmacology,2023

Shafiee, S., Mirzaei, R., Salehi, M., (...), Taheri, A., Farahmand, L.,Synthesized Anti-HER2 .5
Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity,Iranian Journal of
.Immunology,2023

Vafaei, R., Khaki, Z., Salehi, M., (...), Mirzaei, R., Farahmand, L.,Development of a MET-targeted .6
single-chain antibody fragment as an anti-oncogene targeted therapy for breast
.cancer,Investigational New Drugs,2023

Khodabakhsh, F., Shokri, S., Jalili, N., (...), Dashtestani, F., Farahmand, L.,Anti-MUC1 nanobody .7
conjugated by chitosan nanoparticle with enhancement of anti-proliferation activity in breast
.cancer cell lines,Chemical Papers,2023

Ahani, M., Salarian, M., Salehi, M., (...), Taheri, A., Farahmand, L.,Synthesis of Succinimidyl 4- .8
(N-maleimidomethyl)-Cyclohexane-1-Carboxylate (SMCC) as a Linker and Conjugating
Trastuzumab to Maytansinoid Derivative (DM1) Through SMCC as an Antibody-Drug
.Conjugate,Pharmaceutical Chemistry Journal,,2023

Samadi, M., Majidzadeh , A, K., Salehi, M., (...), Moradi , Kalbolandi, S., Farahmand, .9
L.,Correction: Engineered hypoxia-responding Escherichia coli carrying cardiac peptide genes,
suppresses tumor growth, angiogenesis and metastasis in vivo (Journal of Biological
.Engineering,Journal of Biological Engineering,2022

Majidzadeh ,& A, K., Zarinfam, S., Abdoli, N., (...), Salehi, M., Zamani, M.,A comprehensive .10
reference for BRCA1/2 genes pathogenic variants in Iran: published, unpublished and
.novel,Familial Cancer,2022

Merikhian, P., Darvishi, B., Jalili, N., (...), Rahbarizadeh, F., Farahmand, L.,Recombinant .11
nanobody against MUC1 tandem repeats inhibits growth, invasion, metastasis, and
.vascularization of spontaneous mouse mammary tumors,Molecular Oncology,2022

Akhlaghi, M., Taebpour, M., Lotfabadi, N.N., (...), Rahmanian, M., Tofighi, D.,Synthesis and .12
characterization of smart stimuli-responsive herbal drug-encapsulated nanoniosome particles for
.efficient treatment of breast cancer,Nanotechnology Reviews,2022

Darvishi, B., Eisavand, M.R., Majidzadeh ,& A, K., Farahmand, L.,Matrix stiffening and acquired .13
.resistance to chemotherapy: concepts and clinical significance,British Journal of Cancer,2022

Samadi, M., Beigi, L., Yadegari, F., (...), Eskordi, M., Farahmand, L.,Recognition of functional .14
genetic polymorphism using ESE motif definition: a conservative evolutionary approach to
.CYP2D6/CYP2C19 gene variants,Genetica,2022

Ashrafian, S., Zarrineh, M., Jensen, P., (...), Ghassempour, A., Larsen, M.R.,Quantitative .15
Phosphoproteomics and Acetylomics of Safranal Anticancer Effects in Triple-Negative Breast
.Cancer Cells,Journal of Proteome Research,2022

Vafaei, R., Samadi, M., Hosseinzadeh, A., (...), Khaki, Z., Farahmand, L.,Comparison of .16
mucin-1 in human breast cancer and canine mammary gland tumor: a review study,Cancer Cell
.International,2022

Barzaman, K., Vafaei, R., Samadi, M., (...), Dinvari, H., Farahmand, L.,Anti-cancer therapeutic .17
strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk,Cancer Cell
.International,2022

Hosseinzadeh, A., Merikhian, P., Naseri, N., Eisavand, M.R., Farahmand, L.,MUC1 is a .18
potential target to overcome trastuzumab resistance in breast cancer therapy,Cancer Cell

.International,2022

Khodabakhsh, F., Merikhian, P., Eisavand, M.R., Farahmand, L., Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling, *Cancer Cell International*, 2021

Haji Abdolvahab, M., Moradi, kalbolandi, S., Zarei, M., (...), Majidzadeh, A, K., Farahmand, L., Potential role of interferons in treating COVID-19 patients, *International Immunopharmacology*, 2021

Mansouri, S., Mokhtari, Hesari, P., Naghavi, al, Hosseini, F., (...), Ghahremanlou, M., Farahmand, L., Evaluating human epidermal growth factor receptor 2 roles in the efficacy of Tamoxifen treatment in breast cancer, a systematic review, *Pharmacological Reports*, 2021

Barati, M., Javidi, M.A., Darvishi, B., (...), Farahmand, L., Madjid Ansari, A., Necroptosis triggered by ROS accumulation and Ca²⁺ overload, partly explains the inflammatory responses and anti-cancer effects associated with 1Hz, 100 mT ELF-MF in vivo, *Free Radical Biology and Medicine*, 2021

Barzaman, K., Samadi, M., Moradi, & kalbolandi, S., (...), Shekarabi, M., Farahmand, L., Development of a recombinant anti-VEGFR2-EPCAM bispecific antibody to improve antiangiogenic efficiency, *Experimental Cell Research*, 2021

Barzaman, K., Moradi, & Kalbolandi, S., Hosseinzadeh, A., (...), Safari, E., Farahmand, L., Breast cancer immunotherapy: Current and novel approaches, *International Immunopharmacology*, 2021

Moradi, kalbolandi, S., Majidzadeh, A, K., Abdolvahab, M.H., Jalili, N., Farahmand, L., The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development, *Probiotics and Antimicrobial Proteins*, 2021

Samadi, M., Majidzadeh, A, K., Salehi, M., (...), Moradi, Kalbolandi, S., Farahmand, L., Engineered hypoxia-responding Escherichia coli carrying cardiac peptide genes, suppresses tumor growth, angiogenesis and metastasis in vivo, *Journal of Biological Engineering*, 2021

Merikhian, P., Eisavand, M.R., Farahmand, L., Triple-negative breast cancer: understanding Wnt signaling in drug resistance, *Cancer Cell International*, 2021

Darvishi, B., Boroumandieh, S., Majidzadeh, & A, K., (...), Jafari, F., Farahmand, L., The role of activated leukocyte cell adhesion molecule (ALCAM) in cancer progression, invasion, metastasis and recurrence: A novel cancer stem cell marker and tumor-specific prognostic marker, *Experimental and Molecular Pathology*, 2020

Abdolvahab, M.H., Darvishi, B., Zarei, M., Majidzadeh, & A, K., Farahmand, L., Interferons: Role in cancer therapy, *Immunotherapy*, 2020

Rezvani, V., Pourianfar, H.R., Mohammadnejad, S., Madjid Ansari, A., Farahmand, L., Anticancer potentiality and mode of action of low-carbohydrate proteins and peptides from mushrooms, *Applied Microbiology and Biotechnology*, 2020

Rezaei, L., Shojaosadati, S.A., Farahmand, L., Moradi, & Kalbolandi, S., Enhancement of extracellular bispecific anti-MUC1 nanobody expression in E. coli BL21 (DE3) by optimization of temperature and carbon sources through an autoinduction condition, *Engineering in Life Sciences*, 2020

Barzaman, K., Karami, J., Zarei, Z., (...), Safari, E., Farahmand, L., Breast cancer: Biology, biomarkers, and treatments, *International Immunopharmacology*, 2020

Darvishi, B., Salehi, M., Boroumandieh, S., (...), Moradi, & Kalbolandi, S., Farahmand, L., Dual in vitro invasion/migration suppressing and tamoxifen response modulating effects of a recombinant anti-ALCAM scFv on breast cancer cells, *Cell Biochemistry and Function*, 2020

Moradi, Kalbolandi, S., Sharifi, K, A., Darvishi, B., (...), Salehi, M., Farahmand, L., Evaluation the potential of recombinant anti-CD3 nanobody on immunomodulatory function, *Molecular Immunology*, 2020

Moradi, & Kalbolandi, S., Dashtestani, F., Salehi, M., (...), Yadegari, A., Farahmand, L., Development of an anti-CD45RA-quantum dots conjugated scFv to detect leukemic cancer

.stem cells,Molecular Biology Reports,2020

Mokhtari, H., Farahmand, L., Yaserian, K., Jalili, N., Majidzadeh ,& A, K.,The antiproliferative .36
effects of cold atmospheric plasma-activated media on different cancer cell lines, the
implication of ozone as a possible underlying mechanism,Journal of Cellular Physiology,2019

Yadegari, F., Farahmand, L., Esmaili, R., Samadi, T., Majidzadeh, K.,Functional investigation .37
of the BRCA1 Val1714Gly and Asp1733Gly variants by computational tools and yeast
transcription activation assay,Molecular Biology Research Communications,2019

Mansouri, S., Mokhtari , Hesari, P., Naghavi , Al , Hosseini, F., Keivan Majidzadeh, A., .38
Farahmand, L.,The prognostic value of circulating tumor cells in primary breast cancer prior to
any systematic therapy: A systematic review,Current Stem Cell Research and Therapy,2019

Khatibi, A.S., Roodbari, N.H., Majidzade ,& A, K., Yaghmaei, P., Farahmand, L.,Tumor- .39
suppressing and anti-angiogenic activities of a recombinant anti-CD3 \square nanobody in breast
cancer mice model,Immunotherapy,2019

Mahdi, A., Darvishi, B., Majidzadeh ,& A, K., Salehi, M., Farahmand, L.,Challenges facing .40
antiangiogenesis therapy: The significant role of hypoxia-inducible factor and MET in
development of resistance to anti-vascular endothelial growth factor-targeted therapies,Journal
of Cellular Physiology,2019

Imani, M., Kazemi, S., Saviz, M., (...), Sadeghi, B., Faraji ,& dana, R.,Morphological Changes .41
Induced By Extremely Low-Frequency Electric Fields,Bioelectromagnetics,2019

Darvishi, B., Majidzadeh ,& A, K., Ghadirian, R., Mosayebzadeh, M., Farahmand, L.,Recruited .42
bone marrow derived cells, local stromal cells and IL-17 at the front line of resistance
development to anti-VEGF targeted therapies,Life Sciences,2019

Mansouri, S., Feizi, N., Mahdi, A., Majidzadeh ,& A, K., Farahmand, L.,A review on the role of .43
VEGF in tamoxifen resistance,Anti-Cancer Agents in Medicinal Chemistry,2018

Farahmand, L., Mansouri, S., Jafarbeik , Iravani, N., Teymourzadeh, A., Majidzadeh , A, .44
K.,Stemness phenotype in tamoxifen resistant breast cancer cells may be induced by
interactions between receptor tyrosine kinases and ERalpha-66,Recent Patents on Anti-Cancer
Drug Discovery,2018

Darvishi, B., Farahmand, L., Jalili, N., Majidzadeh ,& A, K.,Probable mechanisms involved in .45
immunotoxin mediated capillary leak syndrome (CLS) and recently developed countering
strategies,Current Molecular Medicine,2018

Mansouri, S., Farahmand, L., Teymourzadeh, A., Majidzadeh ,& A, K.,Clinical evidence on the .46
magnitude of change in growth pathway activity in relation to tamoxifen resistance is
required,Current Cancer Drug Targets,2018

Farahmand, L., Merikhian, P., Jalili, N., Darvishi, B., Majidzadeh ,& A, K.,Significant role of .47
MUC1 in development of resistance to currently existing anti-cancer therapeutic agents,Current
Cancer Drug Targets,2018

Esmaili, R., Abdoli, N., Yadegari, F., (...), Kaviani, A., Majidzadeh ,& A, K.,Unique CD44 intronic .48
SNP is associated with tumor grade in breast cancer: A case control study and in silico
analysis,Cancer Cell International,2018

Farahmand, L., Esmaili, R., Eini, L., Majidzadeh ,& A, K.,The effect of mesenchymal stem cell- .49
conditioned medium on proliferation and apoptosis of breast cancer cell line,Journal of Cancer
Research and Therapeutics,2018

Moradi ,& Kalbolandi, S., Hosseinzade, A., Salehi, M., Merikhian, P., Farahmand, L.,Monoclonal .50
antibody-based therapeutics, targeting the epidermal growth factor receptor family: from
herceptin to Pan HER,Journal of Pharmacy and Pharmacology,2018

Farahmand, L., Darvishi, B., Salehi, M., Samadi Kouchaksaraei, S., Majidzadeh ,& A, .51
K.,Functionalised nanomaterials for eradication of CSCs, a promising approach for overcoming
tumour heterogeneity,Journal of Drug Targeting,2018

Seyfoori, A., Samiei, E., Jalili, N., (...), Majidzadeh ,& A, K., Akbari, M.,Self-filling microwell .52

arrays (SFMA) for tumor spheroid formation, Lab on a Chip, 2018

Mansouri, S., Teymourzadeh, A., Farahmand, L., Majidzadeh, & A, K., Challenges of endocrine .53
therapy in breast cancer, Cancer Genetics and Psychotherapy, 2017

Mansouri, S., Naghavi, al, Hosseini, F., Farahmand, L., Majidzadeh, A, K., MED1 may explain .54
the interaction between receptor tyrosine kinases and ER α 66 in the complicated network of
Tamoxifen resistance, European Journal of Pharmacology, 2017

Farahmand, L., Darvishi, B., Majidzadeh, & A, K., Suppression of chronic inflammation with .55
engineered nanomaterials delivering nuclear factor κ B transcription factor decoy
oligodeoxynucleotides, Drug Delivery, 2017

Esmaeili, R., Samadi, T., Abdoli, N., (...), Farahmand, L., Salehi, M., The A-kinase anchoring .56
proteins correlation with disease free survival in breast cancer, Tehran University Medical
Journal, 2017

Darvishi, B., Farahmand, L., Eslami, S, Z., Majidzadeh, A, K., NF- κ B as the main node of .57
resistance to receptor tyrosine kinase inhibitors in triple-negative breast cancer, Tumor
Biology, 2017

Darvishi, B., Panahi, Y., Ghanei, M., Farahmand, L., Investigating Prevalence and Pattern of .58
Long-term Cardiovascular Disorders in Sulphur Mustard-exposed Victims and Determining Proper
Biomarkers for Early Defining, Monitoring and Analysis of Patients' Feedback on Therapy, Basic
and Clinical Pharmacology and Toxicology, 2017

Farahmand, L., Darvishi, B., Majidzadeh, & A, K., Madjid Ansari, A., Naturally occurring .59
compounds acting as potent anti-metastatic agents and their suppressing effects on Hedgehog
and WNT/beta-catenin signalling pathways, Cell Proliferation, 2017

Madjid Ansari, A., Majidzadeh, & A, K., Darvishi, B., (...), Farahmand, L., Norouzi, .60
D., Extremely low frequency magnetic field enhances glucose oxidase expression in Pichia
pastoris GS115, Enzyme and Microbial Technology, 2017

Estiar, M.A., Zare, A., A., Esmaeili, R., (...), Samadi, T., Majidzadeh, A, K., Clinical significance .61
of NDRG3 in patients with breast cancer, Future Oncology, 2017

Darvishi, B., Farahmand, L., Majidzadeh, & A, K., Stimuli-Responsive Mesoporous Silica NPs as .62
Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer, Molecular
Therapy Nucleic Acids, 2017

Merikhian, P., Ghadirian, R., Farahmand, L., Mansouri, S., Majidzadeh, & A, K., MUC1 induces .63
tamoxifen resistance in estrogen receptor-positive breast cancer, Expert Review of Anticancer
Therapy, 2017

Darvishi, B., Farahmand, L., Majidzadeh, & A, K., Patterns of Cancer Stem Cell Negotiation with .64
Breast Cancer Anti-angiogenic Therapy, Breast Journal, 2017

Mansouri, S., Farahmand, L., Hosseinzade, A., Eslami, S, Z., Majidzadeh, A, K., Estrogen can .65
restore Tamoxifen sensitivity in breast cancer cells amidst the complex network of
resistance, Biomedicine and Pharmacotherapy, 2017

Teymourzadeh, A., Mansouri, S., Farahmand, L., Hosseinzade, A., Majidzadeh, & A, K., ER- .66
 α 36 Interactions With Cytosolic Molecular Network in Acquired Tamoxifen
Resistance, Clinical Breast Cancer, 2017

Shariatpanahi, S.P., Jafari, A., Sadeghipour, M., (...), Farahmand, L., Madjid Ansari, .67
A., Assessing the effectiveness of disease awareness programs: Evidence from Google Trends
data for the world awareness dates, Telematics and Informatics, 2017

Estiar, M.A., Esmaeili, R., Zare, A., A., (...), Jafarbeik, Iravani, N., Majidzadeh, A, K., High .68
expression of CEACAM19, a new member of carcinoembryonic antigen gene family, in patients
with breast cancer, Clinical and Experimental Medicine, 2017

Rahmanian, M., Naghib, S.M., Seyfoori, A., (...), Majidzadeh, & A, K., Farahmand, L., Tricalcium .69
phosphate nanostructures loaded with bisphosphonate as potential anticancer agents, Journal of
Ceramic Science and Technology, 2017

- Nikshoar, M.S., Khayamian, M.A., Ansaryan, S., (...), Gity, M., Abdolahad, M., Metas-Chip .70
precisely identifies presence of micrometastasis in live biopsy samples by label free
.approach, Nature Communications, 2017
- Darvishi, B., Farahmand, L., Jalili, N., Majidzadeh, & A, K., Blinatumomab provoked fatal heart .71
.failure, International Immunopharmacology, 2016
- Majidzadeh, A, K., Farahmand, L., Zare, A., A., (...), Salehi, M., Habibi, M., Iranian women's .72
attitude toward prophylactic mastectomy for breast cancer, Journal of Cancer Research and
.Therapeutics, 2016
- Esmaili, R., Majidzadeh, & A, K., Farahmand, L., (...), Salehi, M., Khoshdel, A.R., AKAP3 .73
correlates with triple negative status and disease free survival in breast cancer, BMC
.Cancer, 2015
- Majidzadeh, & A, K., Kaviani, A., Esmaili, R., (...), Olfatbakhsh, A., Moazen, H., Iranian Breast .74
.Cancer Bio-Bank: The activity and challenging issues, Cell and Tissue Banking, 2013
- Farahmand, L., Majidzadeh, & A, K., Sepehrizadeh, Z., (...), Esmaili, R., Yazdi, M.T., Ligation .75
independent cloning of polycistronic, genetically modified, HuMAb4D5-8 F (ab')₂, in bacterial
.plasmid, Avicenna Journal of Medical Biotechnology, 2012